Analysts expect Guardant Health to report Q3 2026 revenue of approximately $350.72 million, representing 32% year-over-year growth, alongside a consensus EPS loss of $0.75. The stock currently trades near $170.73, approximately 11% below the average analyst price target of $191.00.
Investors are primarily focused on the adoption and volume growth of the Shield blood-based colorectal cancer screening test following its landmark FDA approval and the initiation of UnitedHealthcare coverage on August 1, 2026. Market sentiment remains positive as the company leverages recent guideline inclusions from the American Cancer Society and NCCN to expand its commercial footprint in the screening market.
Management's progress toward its goal of becoming free cash flow positive by 2028 and the continued traction of its minimal residual disease (MRD) testing also remain central to the long-term investment thesis.